Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?

Olivier Tournilhac • 19 Jul 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases T-Cell Lymphoma
AATT

Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, discusses the Autologous or Allogeneic Transplantation in T-cell lymphoma (AATT) study. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Screen reader support enabled.

Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, discusses the Autologous or Allogeneic Transplantation in T-cell lymphoma (AATT) study. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Olivier Tournilhac

Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia 2:07
Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
Olivier Tournilhac • 8 Dec 2024
The current outcomes of patients with T-cell lymphoma and the unmet needs that remain 1:27
The current outcomes of patients with T-cell lymphoma and the unmet needs that remain
Olivier Tournilhac • 8 Dec 2024
The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma 4:49
The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma
Olivier Tournilhac • 8 Dec 2020

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals